Publications

Year of Publication Title Faculty Association
2011 Development of potent μ and δ opioid agonists with high lipophilicity. Yeon Sun Lee, Frank Porreca, PhD, Todd Vanderah, PhD
2011 Medroxyprogesterone acetate antagonizes estrogen up-regulation of brain mitochondrial function. Roberta Diaz Brinton, Ph.D
2011 Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions. Roberta Diaz Brinton, Ph.D
2011 Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies. Tally Largent-Milnes, PhD, Frank Porreca, PhD, Todd Vanderah, PhD
2011 Allopregnanolone promotes regeneration and reduces β-amyloid burden in a preclinical model of Alzheimer's disease. Roberta Diaz Brinton, Ph.D
2011 Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment. Roberta Diaz Brinton, Ph.D
2011 Inhibition of p38-MAPK signaling pathway attenuates breast cancer induced bone pain and disease progression in a murine model of cancer-induced bone pain. Frank Porreca, PhD, Todd Vanderah, PhD
2011 Neuroregenerative mechanisms of allopregnanolone in Alzheimer's disease. Roberta Diaz Brinton, Ph.D
2011 2-Deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer's disease. Roberta Diaz Brinton, Ph.D
2010 Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA. Tally Largent-Milnes, PhD, Todd Vanderah, PhD
2010 Oxidative stress increases blood-brain barrier permeability and induces alterations in occludin during hypoxia-reoxygenation. Thomas P Davis, PhD, Jeffrey J. Lochhead, PhD
2010 Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence. Roberta Diaz Brinton, Ph.D
2010 Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance. Tally Largent-Milnes, PhD, Frank Porreca, PhD, Todd Vanderah, PhD
2010 Recently patented and promising ORL-1 ligands: where have we been and where are we going? Tally Largent-Milnes, PhD, Todd Vanderah, PhD
2010 Compensatory hypertrophy induced by ventricular cardiomyocyte-specific COX-2 expression in mice. John M. Streicher, PhD
2010 Clinically relevant progestins regulate neurogenic and neuroprotective responses in vitro and in vivo. Roberta Diaz Brinton, Ph.D
2010 A novel mechanism of acid and bile acid-induced DNA damage involving Na+/H+ exchanger: implication for Barrett's oesophagus. George Watts, Ph.D.
2010 Preserved heart function and maintained response to cardiac stresses in a genetic model of cardiomyocyte-targeted deficiency of cyclooxygenase-2. John M. Streicher, PhD
2010 MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. John M. Streicher, PhD
2010 A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. Tally Largent-Milnes, PhD, Patrick W Mantyh, Todd Vanderah, PhD
2010 Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease. Roberta Diaz Brinton, Ph.D
2010 Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy. Roberta Diaz Brinton, Ph.D
2009 Frontiers proposal. National Institute on Aging "bench to bedside: estrogen as a case study". Roberta Diaz Brinton, Ph.D
2009 Progesterone increases rat neural progenitor cell cycle gene expression and proliferation via extracellularly regulated kinase and progesterone receptor membrane components 1 and 2. Roberta Diaz Brinton, Ph.D
2009 Occludin oligomeric assemblies at tight junctions of the blood-brain barrier are altered by hypoxia and reoxygenation stress. Jeffrey J. Lochhead, PhD

Pages